Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Karolinska

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 20
Average round size
info
The average size of a deal this fund participated in
$11M
Portfolio companies 16
Rounds per year 1.05
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.20
Exits 2
Key employees 1

Areas of investment

  • Biotechnology
  • Medical
  • Pharmaceutical
  • Health Care
  • Biopharma
Summary

Karolinska appeared to be the Corporate Investor, which was created in 2003. The fund was located in Europe if to be more exact in Sweden. The main department of described Corporate Investor is located in the Solna.

Speaking about the real fund results, this Corporate Investor is 6 percentage points less often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2018. Comparing to the other companies, this Karolinska performs on 15 percentage points less the average number of lead investments. The fund is constantly included in less than 2 deals per year. The top amount of exits for fund were in 2019.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Karolinska, startups are often financed by btov Partners, Versant Ventures, Sectoral Asset Management. The meaningful sponsors for the fund in investment in the same round are HealthCap, Almi Invest, Vesalius Biocapital Partners. In the next rounds fund is usually obtained by Novartis Venture Fund, M Ventures, Vesalius Biocapital Partners.

Among the most popular portfolio startups of the fund, we may highlight NsGene, Promimic, OssDsign AB. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Clinical Trials, Health Care. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Sweden.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Karolinska:
Typical Co-investors
Karolinska is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Karolinska:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Alfred Berg Stockholm, Stockholm County, Sweden
Austria Wirtschaftsservice Austria, Vienna
British Airways England, London, United Kingdom
Chayuan Venture Capital Beijing, Beijing, China
Ganexa Capital Lisboa, Lisbon, Portugal
Iyogin Capital Japan, Ota
Joa Investimentos -
Kunlun Capital Central, Central Region, Singapore
Monoful Chiyoda, Japan
Oxford Technology Management Oxford, Oxfordshire, United Kingdom
PTT Public Company Bangkok, Lat Yao Subdistrict, Thailand
Rising Tide Africa -
Sangon Biotech China, Shanghai
South Asia Growth Fund II (SAGFII) -
Third Act Ventures New York, New York, United States
TNN Capital Luxembourg, Luxembourg
Vertex King Of Prussia, Pennsylvania, United States
VILLAGEx District of Columbia, United States, Washington
Xinhu Konggu China, Hangzhou, Zhejiang
Zhonghuicheng Touzi China, Guangdong Province, Longgang District

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Pretzel Therapeutics

Biotechnology
Pharmaceutical
Therapeutics
$72M12 Sep 2022 Waltham, Massachusetts, United States

PharmNovo

Pharmaceutical
$8M03 Jun 2022 Sweden, Skåne County, Sweden

Modus Therapeutics

Biotechnology
Clinical Trials
Pharmaceutical
Therapeutics
$1M12 May 2022 Stockholm, Stockholm County, Sweden

AnaCardio

Biopharma
Medical
$3M03 Feb 2022 Solna, Stockholms Lan, Sweden

AnaCardio

Biopharma
Medical
17 Jun 2021 Solna, Stockholms Lan, Sweden

Aprea

Biotechnology
Health Care
Medical
Personal Health
Pharmaceutical
$59M30 Nov 2018 Stockholm, Stockholm County, Sweden

Forendo Pharma

Health Care
Medical
Pharmaceutical
$4M05 Sep 2018 Southwest Finland

Umecrine Cognition

Biotechnology
Health Care
Pharmaceutical
$2M04 Oct 2017 Sweden, Stockholm County, Sweden

Promimic

Biotechnology
Health Care
Medical Device
Nanotechnology
$3M13 Sep 2016 Gothenburg, Västra Götaland County

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Karolinska?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: